T-Cell Non-Hodgkin’s Lymphoma

Additional Rare Cancer Cases Reported Among Users of TNF Blockers (04-19-2011)

The US Food and Drug Administration (FDA) has received additional reports of a rare type of cancer—hepatosplenic T-cell lymphoma—primarily among adolescents and young adults who are being treated for Crohn’s disease or ulcerative colitis with medications... Continue Reading

Folotyn Benefits Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (02-3-2011)

In the Phase II PROPEL study, 29% of patients with relapsed or refractory peripheral T-cell lymphoma (a type of non-Hodgkin’s lymphoma) experienced a complete or partial disappearance of detectable cancer following treatment with Folotyn® (pralatrexate).... Continue Reading

Istodax Active against Refractory Cutaneous T-cell Lymphoma (08-31-2010)

Final results from a Phase II clinical trial provide additional evidence that Istodax® (romidepsin) is active against refractory cutaneous T-cell lymphoma. These results were published in the Journal of Clinical Oncology. Cutaneous T-cell lymphoma (CTCL)... Continue Reading

Survivors of Some Childhood Cancers May Face Cognitive Impairment (05-18-2010)

Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal... Continue Reading

Children and Teens Have Better NHL Survival than Young Adults (03-15-2010)

Even after accounting for stage at diagnosis and subtype of non-Hodgkin’s lymphoma (NHL), children and teens with NHL have better survival than young adults with NHL. These results were published in the Archives of Pediatrics and Adolescent Medicine. Non-Hodgkin’s... Continue Reading

Allogeneic Stem Cell Transplantation Effective for Angioimmunoblastic T-Cell Lymphoma (07-28-2009)

Among patients with a type of T-cell non-Hodgkin’s lymphoma known as angioimmunoblastic T-cell lymphoma (AITL), treatment with allogeneic stem cell transplantation results in long-term disease-free survival in approximately 50% of patients. The results... Continue Reading

Pralextrate Continues to Show Benefit in Treatment of Peripheral T-Cell Lymphoma (03-8-2009)

Pralextrate Continues to Show Benefit in Treatment of Peripheral T-Cell Lymphoma According to the final results of a Phase II clinical trial, 27% of patients with relapsed or refractory peripheral T-cell lymphoma (a type of non-Hodgkin’s lymphoma)... Continue Reading

Statins May Reduce Effectiveness of Rituxan® in Non-Hodgkin’s Lymphoma (03-8-2009)

Statins May Reduce Effectiveness of Rituxan® in Non-Hodgkin’s Lymphoma Statins may reduce the effectiveness of Rituxan® (rituximab) in treatment of non-Hodgkin’s lymphoma (NHL), according to a recently published article in PLoS Med (the... Continue Reading

The American Society of Clinical Oncology 2008: Advances in Treatment of Lymphoma and Chronic Lymphocytic Leukemia (03-8-2009)

The American Society of Clinical Oncology 2008: Advances in Treatment of Lymphoma and Chronic Lymphocytic Leukemia At the 2008 meeting of the American Society of Clinical Oncology (ASCO), there were more than 100 abstracts devoted to the treatment of... Continue Reading

Pralatrexate Shows Promise Against Peripheral T-cell Lymphoma (12-10-2008)

Pralatrexate Shows Promise Against Peripheral T-cell Lymphoma In a Phase II clinical trial, 27% of patients with relapsed or refractory peripheral T-cell lymphoma (a type of non-Hodgkin?s lymphoma) experienced a complete or partial disappearance of detectable... Continue Reading

« Previous Page